Thursday, 15 October 2026European Markets

MULTICONSULT Stock Bullish Momentum With A 12.71% Jump On Wednesday

Loading stream...

(VIANEWS) - The Market ended the session with MULTICONSULT (MULTI.OL) rising 12.71% to kr168.50 on Wednesday while Oslo Børs Benchmark Index_GI jumped 0.14% to kr1,204.02.

MULTICONSULT's last close was kr149.50, 6.27% below its 52-week high of kr159.50.

About MULTICONSULT

Multiconsult ASA provides engineering design, consultancy, and architecture services in Norway and internationally. The company offers multidisciplinary consultancy, design, planning, project supervision and management, geotechnical site survey, verification and control, analysis and due diligence, construction management, geological investigations, environmental services and HSE, river basin management, hydrometry, and hydrological field work services. It serves buildings and properties, cities and society, industry, oil and gas, renewable energy, rail and transportation, and water and environment sectors. Multiconsult ASA was founded in 1908 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, MULTICONSULT has a trailing twelve months EPS of kr11.05.

PE Ratio

MULTICONSULT has a trailing twelve months price to earnings ratio of 15.25. Meaning, the purchaser of the share is investing kr15.25 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 32.89%.

Sales Growth

MULTICONSULT's sales growth is negative 2% for the present quarter and 5.1% for the next.

Dividend Yield

According to Morningstar, Inc., the next dividend payment is on Apr 14, 2023, the estimated forward annual dividend rate is 9 and the estimated forward annual dividend yield is 6.04%.

Moving Average

MULTICONSULT's value is way higher than its 50-day moving average of kr144.59 and way higher than its 200-day moving average of kr136.26.

More news about MULTICONSULT (MULTI.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com